Cancer Drug Withdrawal Raises Safety Concerns for Lymphoma Patients
New data linking tazemetostat to secondary blood cancers prompts global market withdrawal and trial discontinuation
A cancer drug used to treat certain lymphomas and sarcomas is being withdrawn worldwide after new trial data suggested a possible increased risk of secondary blood cancers. The decision highlights how accelerated approvals depend on confirmatory studies to verify long-term safety and benefit.
Study Details
Tazemetostat, marketed as Tazverik, is an oral ca…
Keep reading with a 7-day free trial
Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.